中国药物警戒 ›› 2016, Vol. 13 ›› Issue (7): 422-425.

• 安全性评价与合理用药 • 上一篇    下一篇

仙灵骨葆胶囊辅助治疗骨质疏松性疼痛疗效与安全性的meta分析

孙丽, 唐汉武   

  1. 广州中医药大学第三附属医院 广东 广州 510000
  • 收稿日期:2016-02-18 修回日期:2018-07-17 出版日期:2016-07-20 发布日期:2018-07-17
  • 作者简介:孙丽，硕士，主管中药师，中药临床药学。

Meta-analysis of Efficacy and Safety of Xianlinggubao Capsule in Adjuvant Treatment of Osteoporosis Pain

SUN Li, TANG Han-wu   

  1. Third Affiliated Hospital of Guangzhou TCM University, Guangdong Guangzhou 510000, China
  • Received:2016-02-18 Revised:2018-07-17 Online:2016-07-20 Published:2018-07-17

PDF (PC)

88

摘要： 目的 系统评价仙灵骨葆胶囊辅助治疗骨质疏松性疼痛的疗效和安全性，以期为临床提供循证参考。方法 检索中文科技期刊全文数据库( CNKI) 、维普数据库、万方数据库，收集仙灵骨葆胶囊治疗骨质疏松性疼痛的随机对照试验（RCT），评价文献质量并提取数据，采用Rev Man 5.3软件进行Meta分析。结果 共纳入6项RCT，合计530例患者。Meta分析结果显示，总有效率[RR=1.27，95% CI(1.16,1.40), P <0.000 01]，差异具有统计学意义；治疗后疼痛VAS评分[RR=-1.54，95% CI(-2.40, -0.68), P <0.05]，差异具有统计学意义；安全性[RR=0.6，95% CI (0.17, 2.07), P >0.05]，差异无统计学意义。结论 仙灵骨葆胶囊辅助治疗骨质疏松性疼痛临床疗效优于对照组，治疗后疼痛程度明显减轻，且联合使用仙灵骨葆胶囊并未增加不良反应的发生。但由于本研究为二次研究，该结论仍有待于进一步证实。

关键词: 仙灵骨葆胶囊, 骨质疏松性疼痛, Meta分析

Abstract: Objective To evaluate the efficacy and safety of Xianlinggubao capsule in the adjuvant treatment of osteoporosis pain, and provide evidence based reference for clinical treatment. Methods Retrieving CNKI, VIP and Wanfang database, randomized controlled trials（RCT）about Xianlinggubao capsule in the adjuvant treatment of osteoporosis pain were collected. After quanlity evaluation and data extraction,Meta-analysis was conducted by using Rev Man 5.3 statistics software. Results 6 RCTs and a total of 530 patients were included. Results of Meta-analysis indicated that, there was significant difference on the total effective rate [RR=1.27, 95%CI(1.16,1.40), P <0.000 01] and VAS [RR=-1.54, 95%CI(-2.40, -0.68), P <0.05]between 2 groups, there was no significant difference on safety [RR=0.6, 95% CI (0.17, 2.07), P >0.05] between 2 groups.Conclusion The clinical effects of the Xianlinggubao capsule group was better than that of the control group, along with a better pain relief and no more occurrence of adverse reactions. But because this study is a secondary research, the conclusion still remains to be further confirmed.

Key words: Xianlinggubao capsule, osteoporosis pain, Meta-analysis

中图分类号: